Expert Review of Neurotherapeutics最新文献_第10页

Bipolar disorder staging and the impact it has on its management: an update. 躁郁症分期及其对治疗的影响：最新进展。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-16 DOI: 10.1080/14737175.2024.2355264

Bernardo Dell'Osso, Laura Cremaschi, Monica Macellaro, Rita Cafaro, Nicolaja Girone

{"title":"Bipolar disorder staging and the impact it has on its management: an update.","authors":"Bernardo Dell'Osso, Laura Cremaschi, Monica Macellaro, Rita Cafaro, Nicolaja Girone","doi":"10.1080/14737175.2024.2355264","DOIUrl":"10.1080/14737175.2024.2355264","url":null,"abstract":"Introduction: The longitudinal course of bipolar disorder (BD) is associated with an active process of neuroprogression, characterized by structural brain alterations and progressive functional impairment. In the last decades, a growing need of a standardized staging model for BD arose, with the aim of a more appropriate definition of stage-specific clinical manifestations and the identification of more customized therapeutic tools.Areas covered: The authors review the literature on clinical aspects, neurobiological correlates and treatment issues related to BD progression. Thereafter, they address the definition, constructs, and evolution of the staging concept, focusing on the clinical applications of BD staging models available in literature.Expert opinion: Although several staging models for BD have been proposed to date, their application in clinical practice is still relatively scant. This may have a detrimental impact on the clinical and therapeutic management of BD, in terms of early and proper diagnosis as well as tailored treatment interventions according to the different stages of illness. Future research efforts should tend to the integration of recent insights on neuroimaging and epigenetic markers, toward a standardized and multidimensional staging model.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"565-574"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review. 用于治疗轻度、中度或重度阿尔茨海默病患者的多奈哌齐透皮系统：评论性综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-24 DOI: 10.1080/14737175.2024.2355981

Austin Buck, Kayvon Rezaei, Aman Quazi, Gary Goldmeier, Bret Silverglate, George T Grossberg

{"title":"The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review.","authors":"Austin Buck, Kayvon Rezaei, Aman Quazi, Gary Goldmeier, Bret Silverglate, George T Grossberg","doi":"10.1080/14737175.2024.2355981","DOIUrl":"10.1080/14737175.2024.2355981","url":null,"abstract":"Introduction: Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with AD and their caregivers.Areas covered: In this drug profile and narrative review, the authors trace the development of the new FDA-approved transdermal donepezil. The authors discuss the studies showing its bioequivalence with the oral formulation, including two double-blinded placebo controlled non-inferiority trials. The authors also compare the patch to the only other transdermal cholinesterase inhibitor on the market, rivastigmine, and highlight the potential advantages and disadvantages between these two treatments.Expert opinion: While the patch is bio-equivalent, it is rather large and may not be affordable for some patients. In addition, there is no high dose (e.g. 23 mg) equivalent. Nevertheless, transdermal donepezil will be useful for people with AD and their caregivers, given its effectiveness and potential convenience.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"24 6","pages":"607-614"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tackling internet gaming disorder: what are the challenges in its treatment? 应对网络游戏障碍：治疗网络游戏障碍面临哪些挑战？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-09 DOI: 10.1080/14737175.2024.2349819

Kristyn Zajac, Meredith K Ginley, Lourah M Kelly, Jessica N Flori, Rory A Pfund

引用次数: 0

Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis. 分析托非森治疗超氧化物歧化酶 1 肌萎缩性脊髓侧索硬化症的效果。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-17 DOI: 10.1080/14737175.2024.2355983

Miguel Oliveira Santos, Mamede de Carvalho

{"title":"Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.","authors":"Miguel Oliveira Santos, Mamede de Carvalho","doi":"10.1080/14737175.2024.2355983","DOIUrl":"10.1080/14737175.2024.2355983","url":null,"abstract":"Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive motor neuron disorder with a fatal outcome 3-5 years after disease onset due to respiratory complications. Superoxide dismutase 1 (SOD1) mutations are found in about 2% of all patients. Tofersen is a novel oligonucleotide antisense drug specifically developed to treat SOD1-ALS patients.Areas covered: Our review covers and discusses tofersen pharmacological properties and its phase I/II and III clinical trials results. Other available drugs and their limitations are also addressed.Expert opinion: VALOR study failed to meet the primary endpoint (change in the revised Amyotrophic Lateral Sclerosis Functional Rating Scale score from baseline to week 28, tofersen arm vs. placebo), but a significant reduction in plasma neurofilament light chain (NfL) levels was observed in tofersen arm (60% vs. 20%). PrefALS study has proposed plasma NfL has a potential biomarker for presymptomatic treatment, since it increases 6-12 months before phenoconversion. There is probably a delay between plasma NfL reduction and the clinical benefit. ATLAS study will allow more insights regarding tofersen clinical efficacy in disease progression rate, survival, and even disease onset delay in presymptomatic SOD1 carriers.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"549-553"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The management of sleep disturbances in children with attention-deficit/hyperactivity disorder (ADHD): an update of the literature. 对注意力缺陷/多动症（ADHD）儿童睡眠障碍的管理：最新文献。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-13 DOI: 10.1080/14737175.2024.2353692

Samuele Cortese, Guilherme Fusetto Veronesi, Alessandra Gabellone, Anna Margari, Lucia Marzulli, Emilia Matera, Maria Giuseppina Petruzelli, Francesco Maria Piarulli, Fabio Tarantino, Alessio Bellato, Valeria Parlatini, Ebba Du Rietz, Henrik Larsson, Samantha Hornsey, Cathy Hill, Lucia Margari

{"title":"The management of sleep disturbances in children with attention-deficit/hyperactivity disorder (ADHD): an update of the literature.","authors":"Samuele Cortese, Guilherme Fusetto Veronesi, Alessandra Gabellone, Anna Margari, Lucia Marzulli, Emilia Matera, Maria Giuseppina Petruzelli, Francesco Maria Piarulli, Fabio Tarantino, Alessio Bellato, Valeria Parlatini, Ebba Du Rietz, Henrik Larsson, Samantha Hornsey, Cathy Hill, Lucia Margari","doi":"10.1080/14737175.2024.2353692","DOIUrl":"10.1080/14737175.2024.2353692","url":null,"abstract":"Introduction: Sleep disorders represent an important comorbidity in individuals with ADHD. While the links between ADHD and sleep disturbances have been extensively investigated, research on the management of sleep disorders in individuals with ADHD is relatively limited, albeit expanding.Areas covered: The authors searched PubMed, Medline, PsycInfo, Embase+Embase Classic, Web of Sciences databases, and clinicaltrials.gov up to 4 January 2024, for randomized controlled trials (RCTs) of any intervention for sleep disorders associated with ADHD. They retained 16 RCTs (eight on pharmacological and eight on non-pharmacological interventions), supporting behavioral intervention and melatonin, and nine ongoing RCTs registered on clinicaltrials.gov.Expert opinion: The pool of RCTs testing interventions for sleep disorders in individuals with ADHD is expanding. However, to inform clinical guidelines, there is a need for additional research in several areas, including 1) RCTs based on a precise phenotyping of sleep disorders; 2) pragmatic RCTs recruiting neurodevelopmental populations representative of those seen in clinical services; 3) trials testing alternative interventions (e.g. suvorexant or light therapy) or ways to deliver them (e.g. online); 4) sequential and longer-term RCTs; 5) studies testing the impact of sleep interventions on outcomes other than sleep; 6) and implementation of advanced evidence synthesis and precision medicine approaches.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"585-596"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140910723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-20 DOI: 10.1080/14737175.2024.2356442

引用次数: 0

Radiosurgical thalamotomy for essential tremor: state of the art, current challenges and future directions. 放射外科丘脑切开术治疗本质性震颤：技术现状、当前挑战和未来方向。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-07 DOI: 10.1080/14737175.2024.2351512

Christian Iorio-Morin, David Mathieu, Andrea Franzini, Mojgan Hodaie, Samuelle-Arianne Villeneuve, Andréanne Hamel, Andres M Lozano

{"title":"Radiosurgical thalamotomy for essential tremor: state of the art, current challenges and future directions.","authors":"Christian Iorio-Morin, David Mathieu, Andrea Franzini, Mojgan Hodaie, Samuelle-Arianne Villeneuve, Andréanne Hamel, Andres M Lozano","doi":"10.1080/14737175.2024.2351512","DOIUrl":"10.1080/14737175.2024.2351512","url":null,"abstract":"Introduction: Essential tremor (ET) is the most frequent movement disorder, affecting up to 5% of adults > 65 years old. In 30-50% of cases, optimal medical management provides insufficient tremor relief and surgical options are considered. Thalamotomy is a time-honored intervention, which can be performed using radiofrequency (RF), stereotactic radiosurgery (SRS), or magnetic resonance-guided focused ultrasounds (MRgFUS). While the latter has received considerable attention in the last decade, SRS has consistently been demonstrated as an effective and well-tolerated option.Areas covered: This review discusses the evidence on SRS thalamotomy for ET. Modern workflows and emerging techniques are detailed. Current outcomes are analyzed, with a specific focus on tremor reduction, complications and radiological evolution of the lesions. Challenges for the field are highlighted.Expert opinion: SRS thalamotomy improves tremor in > 80% patients. The efficacy appears comparable to other modalities, including DBS, RF and MRgFUS. Side effects result mostly from idiosyncratic hyper-responses to radiation, which occur in up to 10% of treatments, are usually self-resolving, and are symptomatic in < 4% of patients. Future research should focus on accumulating more data on bilateral treatments, collecting long-term outcomes, refining targeting, and improving lesion consistency.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"597-605"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the differences in the pharmacological management of post-traumatic stress disorder between women and men. 概述男女在创伤后应激障碍药物治疗方面的差异。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-21 DOI: 10.1080/14737175.2024.2355259

Donatella Marazziti, Lara Foresi Crowther, Alessandro Arone

{"title":"An overview of the differences in the pharmacological management of post-traumatic stress disorder between women and men.","authors":"Donatella Marazziti, Lara Foresi Crowther, Alessandro Arone","doi":"10.1080/14737175.2024.2355259","DOIUrl":"10.1080/14737175.2024.2355259","url":null,"abstract":"Introduction: Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition with a worldwide prevalence between 6% and 9%, and more common in the female than in the male sex. The aim of this paper is to review and comment on the different factors that might explain the discrepancies in the pharmacological management of women and men.Areas covered: The available literature shows that there exists a vulnerability of women to develop PTSD that may depend on neurobiological as well as environmental/cultural factors. These variables might influence the clinical picture, the outcome and the response to specific treatments, given their consequences on the pharmacokinetics of commonly prescribed drugs. Women suffering from PTSD are more prone to consult and receive more prescriptions of psychotropic drugs than men. However, it is evident that the particular stages of a women's life such as pregnancy or breastfeeding might require a specific evaluation and care.Expert opinion: It is necessary to explore the pharmacokinetics of compounds highlighting sex-related differences, and their safety during pregnancy and lactation. Taking care of differences between women and men should represent a main focus of research, while being a primary target towards a really tailored pharmacological treatment of PTSD.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"575-584"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141075867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder. 透视伏替西汀对重度抑郁障碍治疗手段的影响。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-05-01 Epub Date: 2024-03-27 DOI: 10.1080/14737175.2024.2333394

Alessandro Cuomo, Giovanni Barillà, Matteo Cattolico, Simone Pardossi, Elisa Mariantoni, Despoina Koukouna, Pietro Carmellini, Andrea Fagiolini

{"title":"Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder.","authors":"Alessandro Cuomo, Giovanni Barillà, Matteo Cattolico, Simone Pardossi, Elisa Mariantoni, Despoina Koukouna, Pietro Carmellini, Andrea Fagiolini","doi":"10.1080/14737175.2024.2333394","DOIUrl":"10.1080/14737175.2024.2333394","url":null,"abstract":"Introduction: Major Depressive Disorder (MDD) is a mental health issue that significantly affects patients' quality of life and functioning. Despite available treatments, many patients continue to suffer due to incomplete symptom resolution and side effects.Areas covered: This manuscript examines Vortioxetine's role in Major Depressive Disorder (MDD) treatment, highlighting its potential to reshape therapeutic strategies due to its unique Multimodal action and proven broad-spectrum efficacy in multiple depressive domains. A detailed examination of Vortioxetine's pharmacological aspects, including indications, dosage, pharmacodynamics, and pharmacokinetics, is provided, emphasizing its safety and effectiveness. The discussion extends to Vortioxetine's role in acute-phase treatment and maintenance of MDD and its profound impact on specialized depression domains.Expert opinion: Vortioxetine is distinguished for its novel multimodal serotonin modulation mechanism, showcasing significant promise as an innovative treatment for MDD. Its efficacy, which is dose-dependent, along with a commendable tolerability profile, positions it as a potential leading option for initial treatment strategies. The discourse on dosage titration, particularly the strategy of initiating treatment at lower doses followed by gradual escalation, underscores the approach toward minimizing initial adverse effects while optimizing therapeutic outcomes, aligning with the principles of personalized medicine in psychiatric care.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"465-476"},"PeriodicalIF":4.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents. 维洛沙嗪缓释胶囊作为治疗儿童和青少年注意力缺陷/多动症的新兴疗法。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-05-01 Epub Date: 2024-03-19 DOI: 10.1080/14737175.2024.2327533

Vladimir Maletic, Gregory W Mattingly, Jami Earnest

{"title":"Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents.","authors":"Vladimir Maletic, Gregory W Mattingly, Jami Earnest","doi":"10.1080/14737175.2024.2327533","DOIUrl":"10.1080/14737175.2024.2327533","url":null,"abstract":"Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention and/or hyperactivity and impulsivity. Viloxazine extended-release (ER) capsules (Qelbree®) is a US Food and Drug Administration-approved nonstimulant treatment option for children, adolescents, and adults with ADHD.Areas covered: This review manuscript summarizes the neurobiology of ADHD and currently available treatment options before discussing viloxazine pharmacology, efficacy, safety, and tolerability data from phase II and III trials in children and adolescents (6-17 years old). Viloxazine clinical efficacy has also been further demonstrated by post hoc analyses of pediatric clinical trial results.Expert opinion: Current stimulant and nonstimulant treatments for ADHD may be suboptimal given low response rates and that tolerability issues are frequently experienced. Preclinical and clinical evidence has implicated both the role of catecholamine and serotonin signaling in the pathophysiology of ADHD and the pharmacologic effect of viloxazine on these critical neurotransmitter systems. With a relatively rapid onset of action, sustained symptom improvement, and clinical benefit in ADHD-associated impairments (functional and social), viloxazine ER represents a novel and emerging ADHD treatment option.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"443-455"},"PeriodicalIF":4.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0